Breast Studies
CCTG MA.39 Tailor RT
Principal Investigator: Sheema Chawla, MD
Title: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
ClinicalTrials.gov Link: NCT03488693
Gilead ASCENT- 05
Principal Investigator: Farhan Imran, MD
Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer who have Residual Invasive Disease after Surgery and Neoadjuvant Therapy
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
ClinicalTrials.gov Link: NCT05633654
Hematological Neoplasms and Disorder Studies
MM Registry
Principal Investigator: Saad Jamshed, MD
Title: Observational Registry Collecting Data on Patients Diagnosed with Multiple Myeloma
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status: Accruing
MYELOMATCH
Principal Investigator: Maria Sbenghe, MD
Title: MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials
Locations: Rochester General Hospital
Status: Accruing
ClinicalTrials.gov Link: NCT05564390
SID Registry
Principal Investigator: Saad Jamshed, MD
Title: Secondary Immunodeficiency (SID) Registry for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
Celgene CA057 SUCCESSOR-1
Principal Investigator: Saad Jamshed, MD
Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
ClinicalTrials.gov Link: NCT05519085
Thoracic Studies
Alliance A081801
Principal Investigator: Mehul Patel, MD
Title: Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small Cell Lung Cancer: ALCHEMIST CHEMO-IO (ACCIO)
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
VERACYTE NIGHTINGALE
Principal Investigator: Jayashri Bhaskar, MD
Title: Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier – with Familiarization
Locations: Rochester General Hospital
Status: Accruing
Gastrointestinal Studies
ALLIANCE A032103 MODERN
Principal Investigator: Maria Sbenghe, MD
Title: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status: Accruing
ClinicalTrials.gov Link: NCT05987241
ECOG-ACRIN EA2192 APOLLO
Principal Investigator: Amy Bodrog, MD
Title: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status:Accruing
ClinicalTrials.gov Link: NCT04858334
NRG-GI008 CIRCULATE-US
Principal Investigator: Mohammad Talal Khan, DO
Title: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status: Accruing
ClinicalTrials.gov Link: NCT05174169
Locations
Lipson Cancer Institute – Rochester General Hospital
1425 Portland Avenue
Rochester, NY 14621
Lipson Cancer Institute – Linden Oaks
20 Hagen Drive
Suite 100
Rochester, NY 14625
Lipson Cancer Institute – Unity Hospital
1561 Long Pond Road
Suite 120
Rochester, NY 14626
If you would like more information about research studies, please reach out to our staff via email or phone.